Malaysian Genomics Resource Centre Berhad (MGRC), a renowned genomics and biopharmaceutical specialist, has announced a significant partnership with De Cell Berhad to propel the development and commercialization of the pioneering EXOGENETIX program. This collaboration aims to set new standards in the realm of cell-gene therapies.
Through the Strategic Collaboration Agreement (SCA), MGRC Healthcare Sdn. Bhd., a wholly-owned subsidiary of MGRC, will provide technical and production support to optimize the operational efficiency and market deployment of the EXOGENETIX program.
Concurrently, De Cell Berhad will act as the exclusive marketing partner, overseeing all promotional and trademark activities to enhance the program’s market presence and success.
This collaboration underscores MGRC’s commitment to leading innovation and transforming healthcare outcomes through advanced biotechnologies.
By combining MGRC Healthcare’s production capabilities with De Cell Berhad’s marketing expertise, the partnership is poised to significantly advance the reach and effectiveness of the EXOGENETIX program.
Malaysian Genomics, Executive Chairman, Azri Azerai expressed his enthusiasm for the agreement, saying, “We are thrilled to partner with De Cell Berhad to advance the field of cell-gene therapy.
This partnership not only aligns with our strategic vision to deliver cutting-edge healthcare solutions but also reinforces our dedication to pushing the boundaries of medical science.”
De Cell Berhad, Director, Dr. Lim Wooi Khai also commented on the collaboration, saying, “This SCA with MGRC Healthcare represents a significant moment for us at De Cell Berhad. The EXOGENETIX program is a cornerstone of our strategy to bring innovative therapies to the market.”
“Through this partnership, we are set to accelerate the development and delivery of next-generation cell-gene therapies, ultimately improving patient outcomes. We are eager to see the transformative impact this collaboration will have on the healthcare industry.” Dr. Lim added.
This collaboration will focus on broadening the scope and effectiveness of the EXOGENETIX program. By integrating advanced biotechnologies with effective marketing strategies, the strategic alliance aims to address the increasing demand for sophisticated therapeutic options in the biopharmaceutical sector.
